Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00036218
Status:
COMPLETED
Last Update Posted:
2006-06-07
First Post:
2002-05-08
Brief Title:
Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinsons Disease
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Phase III Double-Blind Placebo-Controlled Randomized Study Comparing the Efficacy Safety and Tolerability of Sumanirole Versus Placebo or Ropinirole in Patients With Early Parkinsons Disease
Status:
COMPLETED
Status Verified Date:
2006-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary purpose of this study is to determine whether sumanirole is effective and safe in the treatment of the signs and symptoms of early Parkinsons disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None